About InterMune (NASDAQ:ITMN)
InterMune, Inc. (InterMune) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. On January 2, 2013, it began the commercial launch of Esbriet in Canada. IPF is a disease characterized by progressive scarring, or fibrosis, of the lungs, which leads to their deterioration and destruction. The prognosis is poor for patients with IPF, which occurs primarily in persons 40 to 70 years old with a median survival time from diagnosis of two to five years. Pirfenidone in Japan is sold by Shionogi under the brand name Pirespa. Pirfenidone in India is sold by Cipla Ltd. under the brand name Pirfenex, and in China is sold by Shanghai Genomics. In September 2014, Roche Holding AG acquired InterMune.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
InterMune (NASDAQ:ITMN) Frequently Asked Questions
What is InterMune's stock symbol?
InterMune trades on the NASDAQ under the ticker symbol "ITMN."
Who are some of InterMune's key competitors?
Some companies that are related to InterMune include Iqvia (IQV), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Seattle Genetics (SGEN), Nektar Therapeutics (NKTR), Alkermes (ALKS), Qiagen (QGEN), Sage Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), EXACT Sciences (EXAS), Covance (CVD), Icon (ICLR), United Therapeutics (UTHR), PRA Health Sciences (PRAH), Charles River Laboratories International (CRL), Bio-Techne (TECH), Anacor Pharmaceuticals (ANAC) and Galapagos (GLPG).
How do I buy InterMune stock?
Shares of InterMune can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact InterMune?
InterMune's mailing address is 3280 Bayshore Blvd, BRISBANE, CA 94005-1021, United States. The biotechnology company can be reached via phone at +1-415-4662200.
MarketBeat Community Rating for InterMune (ITMN)MarketBeat's community ratings are surveys of what our community members think about InterMune and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
InterMune (NASDAQ:ITMN) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
InterMune (NASDAQ:ITMN) Earnings History and Estimates Chart
InterMune (NASDAQ ITMN) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/6/2014||Q214||($0.56)||($0.72)||$33.96 million||$35.70 million||View||Listen|
|5/1/2014||Q114||($0.62)||($0.59)||$28.24 million||$30.30 million||View||Listen|
|7/24/2013||Q2 2013||($0.70)||($0.77)||$12.95 million||$14.40 million||View||Listen|
|4/24/2013||Q1 2013||($0.73)||($0.64)||$10.53 million||$10.53 million||View||Listen|
|2/21/2013||Q4 2012||($0.87)||($0.90)||$8.31 million||$8.20 million||View||Listen|
|11/7/2012||Q312||($0.83)||($0.70)||$6.31 million||$7.50 million||View||N/A|
InterMune (NASDAQ:ITMN) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for InterMune (NASDAQ:ITMN)
No dividend announcements for this company have been tracked by MarketBeat.com
InterMune (NASDAQ ITMN) Insider Trading and Institutional Ownership History
InterMune (NASDAQ ITMN) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/2/2014||Andrew Kenneth William Powell||EVP||Sell||7,500||$73.47||$551,025.00|| |
|8/13/2014||Paul D Arata||EVP||Sell||7,500||$50.00||$375,000.00|| |
|8/11/2014||John Hodgman||CFO||Sell||4,724||$43.05||$203,368.20|| |
|8/7/2014||Daniel G Welch||CEO||Sell||171,025||$44.98||$7,692,704.50|| |
|7/17/2014||Paul D Arata||EVP||Sell||2,382||$41.00||$97,662.00|| |
|7/15/2014||Jonathan A Leff||EVP||Sell||35,000||$43.08||$1,507,800.00|| |
|6/18/2014||Sean P Nolan||EVP||Sell||10,000||$47.10||$471,000.00|| |
|6/16/2014||Daniel G Welch||CEO||Sell||15,000||$45.02||$675,300.00|| |
|6/13/2014||Sean P Nolan||EVP||Sell||20,000||$42.80||$856,000.00|| |
|6/4/2014||Daniel G Welch||CEO||Sell||3,914||$39.19||$153,389.66|| |
|6/3/2014||John Hodgman||CFO||Sell||1,201||$38.78||$46,574.78|| |
|6/3/2014||Jonathan A Leff||EVP||Sell||1,153||$38.78||$44,713.34|| |
|5/30/2014||Daniel G Welch||CEO||Sell||4,565||$40.06||$182,873.90|| |
|5/29/2014||David S Kabakoff||Director||Sell||5,000||$39.56||$197,800.00|| |
|5/27/2014||Daniel G Welch||CEO||Sell||41,493||$40.03||$1,660,964.79|| |
|5/19/2014||Sean Nolan||EVP||Sell||7,500||$39.50||$296,250.00|| |
|5/8/2014||Sean Nolan||VP||Sell||2,644||$35.85||$94,787.40|| |
|5/6/2014||Daniel Welch||CEO||Sell||60,432||$34.76||$2,100,616.32|| |
|3/4/2014||Jonathan Leff||EVP||Sell||27,361||$30.95||$846,822.95|| |
|3/4/2014||Nepi Giacomo Di||Director||Sell||70,000||$30.84||$2,158,800.00|| |
|1/10/2014||Daniel Welch||CEO||Sell||50,000||$17.00||$850,000.00|| |
|12/2/2013||Daniel Welch||CEO||Sell||20,000||$13.99||$279,800.00|| |
|10/1/2013||Daniel G Welch||CEO||Sell||70,000||$15.43||$1,080,100.00|| |
|8/30/2013||David Kabakoff||Director||Sell||10,002||$14.82||$148,229.64|| |
|8/27/2013||Angus Russell||Director||Buy||6,600||$14.53||$95,898.00|| |
InterMune (NASDAQ ITMN) News Headlines
InterMune (NASDAQ:ITMN) SEC Filings
InterMune (NASDAQ:ITMN) Income Statement, Balance Sheet and Cash Flow Statement
InterMune (NASDAQ ITMN) Stock Chart for Tuesday, December, 12, 2017